MedDataX Logo

Glycemic Load & Resistance Training on Endothelial Function & Insulin Sensitivity

NCT ID: NCT01755962

Last Updated: 2020-11-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

88 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-04-30

Study Completion Date

2017-12-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This project is prompted by the urgent public health need to identify novel strategies to prevent cardiovascular disease (CVD) and type 2 diabetes (T2D). The higher prevalence of CVD, T2D, and metabolic syndrome in obese individuals is a major healthcare concern. Therefore, finding optimal intervention strategies to combat these growing epidemics is imperative.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

At present, the extent to which dietary components can modify endothelial function, monocyte inflammation and glycemic variations is not well defined, although different carbohydrates are known to vary in their abilities to induce plasma glucose and insulin responses. Epidemiologic work suggests that high dietary glycemic load (GL) is associated with increased concentrations of inflammatory cytokines, endothelial dysfunction markers, and increased risk of T2D and coronary heart disease (CHD). We are examining using randomized control trials low vs. high-GL diet to determine if low-GL diets induce improvements in endothelial function or monocyte inflammation. Furthermore, resistance training is an alternate form of exercise from conventional aerobic training. Resistance Training has the potential to improve endothelial function or monocyte phenotype, but there is very little data in this area. We hypothesize that resistance training may augment the beneficial effects of a low-GL diet in improving metabolic health.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

160 Participants Aged 18-35 Years and Obese (BMI ≥30) Open to Men and Women of All Ethnicity

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

diet obese overweight exercise resistance training nutrition glycemic load body composition weight training lifestyle

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

There are four intervention arms designed to compare two factors, glycemic load and resistance training. Arms consist of high glycemic diet, no exercise, high glycemic diet, resistance training; low glycemic diet, no exercise; low glycemic diet, resistance training.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low Glycemic Load + Resistance Training

12-week intervention diet + resistance training (1 hour, 3 times per week)

Group Type EXPERIMENTAL

Glycemic Load

Intervention Type OTHER

Resistance Training

Intervention Type OTHER

High Glycemic Load + Resistance Training

12-week control diet + resistance training (1 hour, 3 times per week)

Group Type EXPERIMENTAL

Glycemic Load

Intervention Type OTHER

Resistance Training

Intervention Type OTHER

Low Glycemic Load

12-week intervention diet

Group Type EXPERIMENTAL

Glycemic Load

Intervention Type OTHER

High Glycemic Load

12-week control diet

Group Type OTHER

Glycemic Load

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Glycemic Load

Intervention Type OTHER

Resistance Training

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18-35 with BMI≥30 and/or your waist circumference ≥40 inches for males or ≥35 inches for females
* In good health as determined by the screening visit and review of medical history

Exclusion Criteria

* Have a known heart arrhythmia and/or abnormalities found in electrocardiogram (ECG) reading or use of medications that influence CV function
* Have been in a weight loss or exercise program in the 6 months prior to participation
* Use tobacco products
* Have a syndrome or are prescribed medications that may influence body composition, insulin action, or CVD (e.g. PCOS, prednisone, methylphenidate, etc.)
* Have intolerance to lactose or gluten
* Pregnant
Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of California, Los Angeles

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Catherine Carpenter, PhD, MPH

Role: PRINCIPAL_INVESTIGATOR

University of California, Los Angeles

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of California, Los Angeles

Los Angeles, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

546464

Identifier Type: -

Identifier Source: org_study_id